The originating document has been archived. We cannot confirm the completeness, accuracy and currency of the content.
Pronunciation: pihr-BYOO-tuh-role ASS-uh-TATE
- Aerosol 0.2 mg/actuation
Produces bronchodilation by relaxing bronchial smooth muscle through beta-2 receptor stimulation.
Rapidly absorbed following aerosol administration.
51% of the dose is excreted in the urine plus its sulfate conjugate. T ½ and plasma is approximately 2 h (oral).
5 min (inhalation).
5 h (inhalation).
Indications and Usage
Prevention and treatment of reversible bronchospasm associated with asthma or other obstructive pulmonary diseases.
Hypersensitivity to drug components; cardiac arrhythmias associated with tachycardia.
Dosage and AdministrationAdults and Children 12 yr of age and older
Inhalation 1 to 2 inhalations every 4 to 6 h; not to exceed 12 inhalations/day.
Store at room temperature.
Drug InteractionsMAOIs, tricyclic antidepressants
May increase the effects of pirbuterol.
Laboratory Test Interactions
None well documented.
Palpitations; tachycardia; BP changes; chest tightness/pain/discomfort; angina; arrhythmias/skipped beats.
Tremor; anxiety; confusion; fatigue; dizziness; nervousness; headache; weakness; hyperactivity/hyperkinesia/excitement; insomnia.
Dry nose; throat irritation.
GI distress; dry mouth; diarrhea; nausea/vomiting.
Cough; throat irritation.
Flushing; anorexia/appetite loss; unusual/bad taste; taste/smell change.
Category C .
Safety and efficacy in children 12 yr of age and younger not established.
Lower doses may be required.
Labor and Delivery
May inhibit uterine contractions and delay preterm labor.
Toxic symptoms in patients with CV disorders may occur.
CNS stimulation may occur; use cautiously in patients with history of seizure or hyperthyroidism.
Dosage adjustment of insulin or oral hypoglycemic agent may be required.
Paradoxical bronchospasm and cardiac arrest have been associated with excessive inhalant use.
Decreases in potassium levels have occurred.
If previously effective dose fails to provide relief therapy may need to be reassessed.
Tremor, palpitations, tachycardia, elevated blood pressure, anginal pain, hypokalemia, seizures.
- Advise patient to take drug early in day to prevent insomnia.
- Explain that implementing therapy in morning and after meals may reduce fatigue and improve lung ventilation.
- Encourage patient to increase fluid intake to help liquify secretions.
- Tell patient to report the following symptoms to health care provider: Dizziness, chest pain, palpitations, muscle spasms, headache, difficult urination, dyspnea or nervous tremor.
- Explain that if no relief is obtained from normal daily dose, call health care provider instead of increasing dose. Also if more than 3 aerosol treatments are needed in 24 h, notify health care provider.
- Tell patient to wait at least 1 to 2 min before administering second inhalation.
- Instruct patient that regular, consistent use of medication is required for maximum benefits.
- Explain benefits of and demonstrate technique for postural drainage and chest vibration.
- Emphasize that it is important to avoid getting aerosol medication in eyes.
- Tell patient to avoid smoking, smoke-filled rooms, and persons with respiratory infections.
- Explain how to use and care for inhalers and any other respiratory equipment.
Copyright © 2009 Wolters Kluwer Health.